BRPI0414968A - preparação de infusão contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo - Google Patents

preparação de infusão contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo

Info

Publication number
BRPI0414968A
BRPI0414968A BRPI0414968-8A BRPI0414968A BRPI0414968A BR PI0414968 A BRPI0414968 A BR PI0414968A BR PI0414968 A BRPI0414968 A BR PI0414968A BR PI0414968 A BRPI0414968 A BR PI0414968A
Authority
BR
Brazil
Prior art keywords
infusion
acid
active ingredient
salt
infusion preparation
Prior art date
Application number
BRPI0414968-8A
Other languages
English (en)
Inventor
Masao Sudoh
Seiichi Tanikawa
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BRPI0414968A publication Critical patent/BRPI0414968A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PREPARAçãO DE INFUSãO CONTENDO áCIDO (2R)-2-PROPILOCTANóICO COMO O INGREDIENTE ATIVO". Uma preparação de infusão que contém ácido (2R)-2propiloctanóico ou um sal do mesmo, útil no tratamento de doenças neurodegenerativas, e um íon de metal básico fornecido a partir de um sal de metal de um ácido fraco ou um hidróxido de metal preferivelmente em uma quantidade de cerca de 1 a 5 equivalentes por por equivalente do ácido (2R)-2-própiloctanóico ou um sal do mesmo, opcionalmente em conjunto com outro (s) componente(s) de infusão. Essa preparação de infusão apresenta um valor de pH adequado para administração intravenosa, e é útil em administração intravenosa contínua sem a necessidade de qualquer pré-tratamento tal como dissolução ou diluição antes do uso.
BRPI0414968-8A 2003-10-03 2004-10-01 preparação de infusão contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo BRPI0414968A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003345125 2003-10-03
PCT/JP2004/014896 WO2005032538A1 (ja) 2003-10-03 2004-10-01 (２ｒ)−２−プロピルオクタン酸を有効成分とする輸液製剤

Publications (1)

Publication Number Publication Date
BRPI0414968A true BRPI0414968A (pt) 2006-11-07

Family

ID=34419442

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414968-8A BRPI0414968A (pt) 2003-10-03 2004-10-01 preparação de infusão contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo

Country Status (17)

Country Link
US (1) US20070066686A1 (pt)
EP (1) EP1669066A4 (pt)
JP (1) JP4715516B2 (pt)
CN (1) CN1889941A (pt)
AU (1) AU2004277828A1 (pt)
BR (1) BRPI0414968A (pt)
CA (1) CA2540671A1 (pt)
EC (1) ECSP066476A (pt)
IL (1) IL174691A0 (pt)
IS (1) IS8428A (pt)
MA (1) MA28143A1 (pt)
MX (1) MXPA06003605A (pt)
NO (1) NO20061458L (pt)
RU (1) RU2006114834A (pt)
SG (1) SG146690A1 (pt)
WO (1) WO2005032538A1 (pt)
ZA (1) ZA200602689B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7980168B2 (en) * 2007-06-26 2011-07-19 Maurer Scott D Hot beverage maker with filter deforming member
US20100130619A1 (en) * 2008-11-24 2010-05-27 Joseph Schwarz Pharmaceutical composition for parenteral administration of idebenone
RU2549448C1 (ru) * 2014-05-20 2015-04-27 Екофарм Патент Менеджмент Аг Сбалансированный инфузионный раствор
CN104931424A (zh) * 2015-05-06 2015-09-23 山东师范大学 一种改进的z扫描非线性测量的实验装置及方法
CN109593676B (zh) * 2018-12-21 2023-04-07 江苏大学 一种用于酸菜发酵液中微生物分离的培养基及其制备方法
CA3129732A1 (en) * 2019-02-14 2020-08-20 North Grove Investments, Inc. Compositions for maintaining the viability of living and static biological material, methods of making and the uses thereof
RU2699222C1 (ru) * 2019-04-29 2019-09-04 Алексей Владимирович Воронов Солевой электролитный раствор для проведения энтеральных инфузий

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE163006T1 (de) * 1993-06-01 1998-02-15 Ono Pharmaceutical Co Pentansäurederivate
JPH0782146A (ja) * 1993-07-23 1995-03-28 Sagami Chem Res Center 抗痴呆薬
JPH07285911A (ja) * 1994-04-20 1995-10-31 New Japan Chem Co Ltd 脂肪族モノカルボン酸組成物
JPH0853351A (ja) * 1994-08-11 1996-02-27 Sagami Chem Res Center 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
TWI268921B (en) * 1999-02-18 2006-12-21 Ono Pharmaceutical Co A process for preparing (2R)-2-propyloctanoic acid
EP1295893A4 (en) * 2000-05-31 2005-10-26 Japan Science & Tech Agency GINSENOSIDES FOR PROMOTING SKIN WEBERENEGENERATION
KR100759771B1 (ko) * 2000-07-18 2007-10-04 오노 야꾸힝 고교 가부시키가이샤 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제
JP4706950B2 (ja) * 2000-07-18 2011-06-22 小野薬品工業株式会社 アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤
JP4178405B2 (ja) * 2001-07-18 2008-11-12 小野薬品工業株式会社 脳虚血疾患治療剤

Also Published As

Publication number Publication date
JPWO2005032538A1 (ja) 2006-12-14
EP1669066A1 (en) 2006-06-14
IL174691A0 (en) 2006-08-20
CN1889941A (zh) 2007-01-03
AU2004277828A1 (en) 2005-04-14
WO2005032538A1 (ja) 2005-04-14
ECSP066476A (es) 2007-03-29
MXPA06003605A (es) 2006-06-14
IS8428A (is) 2006-04-25
US20070066686A1 (en) 2007-03-22
SG146690A1 (en) 2008-10-30
NO20061458L (no) 2006-07-03
RU2006114834A (ru) 2007-11-20
JP4715516B2 (ja) 2011-07-06
CA2540671A1 (en) 2005-04-14
ZA200602689B (en) 2007-06-27
EP1669066A4 (en) 2009-04-29
MA28143A1 (fr) 2006-09-01

Similar Documents

Publication Publication Date Title
ECSP066477A (es) Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo
WO2008108286A1 (ja) 経皮吸収医薬組成物、医薬組成物貯蔵ユニットおよびこれを利用する経皮吸収製剤
EP1626055A3 (en) Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system
EP2392322A3 (en) Dosing regimes for trans-clomiphene
TW200500067A (en) Salts of codrugs and uses related thereto
ATE545407T1 (de) Pharmazeutische formulierung von apomorphin für die bukkale verabreichung
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
BRPI0916282B8 (pt) uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica
ECSP066476A (es) Preparación de una infusión que comprende ácido (2r)-2-propiloctanoico como ingrediente activo
ATE539761T1 (de) Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
WO2012044783A8 (en) Method of achieving a thymosin beta 4 concentration in a human patient
Dehpour et al. Inhibition of the morphine withdrawal syndrome and the development of physical dependence by lithium in mice
BR112015022084A2 (pt) composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
RU2006109966A (ru) Препарат "янтастим-с" для терапии и профилактики инфекционных заболеваний животных
BRPI0410851A (pt) solução aquosa de olanexidina, método de preparação da solução aquosa e desinfetante
TW200626133A (en) Oral medication for twice-daily administration
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
RU2012114097A (ru) Терапевтический агент против хронической боли
BR0317292A (pt) Derivados de amida de ácido antranìlico e seu uso farmacêutico
DOP2005000052A (es) Preparacion de infusión que comprende acido (2r)-2-propilactanoico como un ingrediente activo
BR0312333A (pt) Terapia de combinação e agente para sua execução
DOP2005000053A (es) Composicion farmaceutica que comprende acido (2r)-2-propilactanoico como un ingrediente activo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.